Home › Salivary Gland Cancer › New York
Salivary Gland Cancer clinical trials in New York
5 studies for Salivary Gland Cancer are looking for participants at sites in New York.
Cities in New York
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Mount Sinai Hospital, New York
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05408845A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 10, 2026 · NCT06695845Integrated Cancer Repository for Cancer Research
- C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls
- Faxton St. Luke's Healthcare, Mohawk Valley, Utica
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT04620187VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Weill Cornell Medicine, Cornell University (site 126), New York
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Dec 11, 2025 · NCT03556228From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.